Lineage Cell Therapeutics Inc. Common Stock (LCTX)
Stock · AMEX · Health Care
$0.989as of 10/16/2026
Price chart
Active signals
LCTX Signal Track Record
How signals performed across all stocks →What LCTX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 46 | -2.7% | 46% | September 14, 2026 |
| Bollinger Band Breakout | 26 | -5.5% | 38% | June 29, 2026 |
| Bollinger Band Breakdown | 19 | -2.1% | 42% | September 23, 2026 |
| 200-Day Moving Average TouchActive now | 19 | +0.7% | 53% | April 23, 2026 |
| Any 20-session window (baseline) | -1.4% | 44% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About LCTX
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 72
- Website
- lineagecell.com/
Fundamentals
- 1-day range
- $0.918$0.9984
- Market cap
- $281.71M
- P/E (trailing)
- —
- P/E (forward)
- -7.20
- EPS (trailing)
- $-0.14
- Dividend yield
- —
- Beta
- 1.67
- Avg. volume
- 1.22M
How Lineage Cell Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 5, 2026 · via SEC EDGAR / Finnhub
Forecasts
6 analyst ratings
Lineage Cell Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- LCTXLineage Cell Therapeutics Inc. Common Stock$0.98▼ 1.01%Market cap $281.71MP/E —$0.8823$2.09
- EDITEditas Medicine Inc. Common Stock$2.35▼ 3.69%Market cap $283.93MP/E —$1.66$4.33
- FATEFate Therapeutics Inc. Common Stock$1.79▼ 7.25%Market cap $290.23MP/E —$0.95$3.23
- SABSSAB Biotherapeutics Inc. Common Stock$2.53▼ 2.32%Market cap $294.39MP/E 17.75$2.1$5.15
- NMRANeumora Therapeutics Inc. Common Stock$0.474▲ 11.01%Market cap $303.87MP/E —$0.3154$3.65
- AVXLAnavex Life Sciences Corp. Common Stock$1.31▼ 11.49%Market cap $303.96MP/E —$1.56$10.38
- SRZNSurrozen Inc. Common Stock$23.44▼ 6.50%Market cap $251.25MP/E —$11.39$37.83
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| LCTX Lineage Cell Therapeutics Inc. Common Stock | $281.71M | — | $0.98 | ▼ 1.01% | $0.8823$2.09 |
| EDIT Editas Medicine Inc. Common Stock | $283.93M | — | $2.35 | ▼ 3.69% | $1.66$4.33 |
| FATE Fate Therapeutics Inc. Common Stock | $290.23M | — | $1.79 | ▼ 7.25% | $0.95$3.23 |
| SABS SAB Biotherapeutics Inc. Common Stock | $294.39M | 17.75 | $2.53 | ▼ 2.32% | $2.1$5.15 |
| NMRA Neumora Therapeutics Inc. Common Stock | $303.87M | — | $0.474 | ▲ 11.01% | $0.3154$3.65 |
| AVXL Anavex Life Sciences Corp. Common Stock | $303.96M | — | $1.31 | ▼ 11.49% | $1.56$10.38 |
| SRZN Surrozen Inc. Common Stock | $251.25M | — | $23.44 | ▼ 6.50% | $11.39$37.83 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Transcript: Lineage Cell Therapeutics Q2 2026 Earnings Conference Callbenzinga · 10/12/2026
- 3 Small Cap Stocks With Strong Revenue Growth And Low DebtYahoo · 9/16/2026
Insider Activity
Insider Actions →- Amin Dipti · July 1, 2026 · Grant125.0K
- Anula Jayasuriya · July 1, 2026 · Grant125.0K
- Russell Angus C. · July 1, 2026 · Grant125.0K
- Michael H. Mulroy · July 1, 2026 · Grant125.0K
- Deborah J. Andrews · July 1, 2026 · Grant125.0K
- Bradsher Neal C · July 1, 2026 · Grant125.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 110.37M
- Total value held
- $173.57M
- Institutional holders
- 126
- Unknown49.56M
- Unknown8.32M
- Unknown6.73M
- Unknown5.56M
- Unknown5.36M
- Unknown4.60M
- Unknown3.86M
- Unknown3.18M
- Unknown3.07M
- Unknown2.52M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
LCTX Holds Q2 2026 Earnings Conference Call
Lineage Cell Therapeutics held its Q2 2026 earnings conference call, with a transcript released by Benzinga. Management reviewed the quarter's financial results and gave updates on ongoing clinical programs. The discussion provides investors with current insight into the company's performance and future plans. The call occurs while the stock is near its recent support level.
LCTX Holds Q2 2026 Earnings Conference Call. Lineage Cell Therapeutics held its Q2 2026 earnings conference call, with a transcript released by Benzinga. Management reviewed the quarter's financial results and gave updates on ongoing clinical programs. The discussion provides investors with current insight into the company's performance and future plans. The call occurs while the stock is near its recent support level.